Kornimate/medical-research-clean huggingface dataset:
association of picp serum marker in patients with lvsd

Conditions: Systolic Dysfunction

Summary: the purpose of this study is to determine if the carboxy-terminal of procollagen type i (picp) can be a useful marker of different degrees of myocardial fibrosis.

abnormality of diastolic function, particularly a more advanced form known as restrictive tilling pattern, has been correlated with worse outcome in patients with systolic dysfunction associated with chronic heart failure or following an acute myocardial infarction. recently, the severity of diastolic dysfunction has also been shown to predict the response to cardiac synchronization therapy for refractory heart failure due to systolic dysfunction. varying degree of diastolic dysfunction has been reported among patients with comparable severity of systolic dysfunction. the underlying mechanisms responsible for the observed discordance between systolic and diastolic dysfunction in these patients remains incompletely understood. the carboxy-terminal of procollagen type i (picp), a peptide that is cleaved from procollagen type i during the synthesis of fibril-forming collagen type i, has been associated with myocardial fibrosis. myocardial fibrosis is a major determinant of both systolic and diastolic function of the heart. we hypothesize that differential degrees of myocardial fibrosis may be responsible for these discrepancies.

Eligibility criteria:
inclusion criteria: 1. evidence of left ventricular systolic dysfunction (measured lvef% less than 35%) measured by echocardiography within the previous three months at the time of enrollment 2. greater than or equal to 18 years of age 3. greater than or equal to 110 pounds in weight exclusion criteria: 1.non-sinus rhythm at the time of enrollment

Keywords: ejection fraction <35%
an observational study to evaluate the real-world clinical management and outcomes of alk-positive advanced nsclc participants treated with alectinib

Conditions: NSCLC

Summary: this study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc) who are being treated with alectinib in real-world clinical practice.


Eligibility criteria:
inclusion criteria * confirmed diagnosis of advanced nsclc (stage iiib, iiic, iva, or ivb) on or after the date of local approval for alectinib as first-line treatment and/or second-line treatment for alk-positive advanced nsclc and planned to receive treatment as per routine for at least one cycle (28 days) while on study * alk-positive as confirmed by immunohistochemistry (ihc), fluorescent in situ hybridization (fish), next generation sequencing (ngs), or other non-specified sequencing methods, documented prior to receiving treatment with an alk inhibitor * cohort 1: currently receiving, or planned to receive, treatment for alk-positive advanced nsclc with alectinib as first-line treatment * cohort 2: planned to receive treatment for alk-positive advanced nsclc with alectinib as second-line treatment * able to be followed-up by participating site * participants with advanced nsclc who have cns metastases are eligible for inclusion exclusion criteria * participants not receiving alectinib for the treatment of alk-positive advanced nsclc according to standard of care and in line with local product information * participants not receiving the roche studied medicinal product * participants who have received or are currently receiving alectinib as an investigational study drug in a clinical trial for the treatment of advanced nsclc

Keywords: alk-positive nsclc
electromyographic calibration guided by depth of anesthesia

Conditions: Neuromuscular Blockade

Summary: the goal of the celeste study is to evaluate whether calibration of emg is needed for reliable interpretation of neuromuscular function and if so, to identify the minimal necessary depth of anesthesia.

neuromuscular monitoring is used to document neuromuscular function intra-operatively. failure to restore neuromuscular function prior to extubation results in residual neuromuscular blockade which is associated with increased postoperative morbidity and mortality. it is essential to document baseline neuromuscular function before administration of the neuromuscular blocking agent. however, during anesthesia induction, neuromuscular monitoring is rarely calibrated due to its time-consuming nature coinciding with the patients' loss of consciousness. the celeste trial is a randomized, prospective, observational proof-of-concept study. we plan to enroll sixty adult participants scheduled for elective non-cardiac surgery requiring general anesthesia with moderate neuromuscular blockade. participants will be randomized into three electromyography (emg) calibration groups: based on state entropy ("depth of anesthesia"), group 1 will receive "analgesic calibration", group 2 "sedated calibration", and group 3 "no calibration". participants will be randomly allocated to receive calibration at a certain depth of anesthesia. all participants will receive a standard emg performed on the contralateral arm. standard emg will be calibrated at state entropy of 50.

Eligibility criteria:
inclusion criteria: * signed informed written consent * bmi 17.5-30 kg/m\^2 * asa \<= 3 * supine positioning during surgery with intraoperative access to both arms * absence of allergy to muscle relaxants and reversal agents * absence of neuromuscular disease exclusion criteria: * ambulatory patients for whom discharge is planned within 12 hours of anaesthesia * patients undergoing minor surgical * procedures scheduled outside the operating room * patients who are endotracheally intubated prior to surgery * pregnancy * indication for rapid sequence induction * patients undergoing arm surgery * patients with preceding injuries impairing muscle or nerve function of the arm (e.g., finger amputation)

Keywords: electromyography calibration residual paralysis
intrapartum study of sterile and clean gloves

Conditions: Chorioamnionitis

Summary: the purpose of this study is to determine whether the use of sterile or clean gloves during labor exams affects the rate of chorioamnionitis. chorioamnionitis is an infection of the membranes around the baby.

the importance of this study is that intrapartum vaginal exams (while patients are laboring) are performed routinely in modern obstetrical practice, and there is no randomized trial available assessing the relationship between the type of glove used and the rate of chorioamnionitis.

Eligibility criteria:
inclusion criteria: * spontaneous or induced labor * rupture of membranes \< 12 hours * nulliparous or multiparous * gestational age greater than or equal to 34 weeks * age greater than or equal to 18 exclusion criteria: * contraindications to labor * multiple gestations * rupture of membranes greater than 12 hours * gestational age less than 34 weeks * non-english speaking patients

Keywords: intrapartum glove chorioamnionitis
risk-adapted strategy including magnetic resonance imaging and prostate-specific antigen density in blood for biopsy decision in patients with lesions suspicious for prostate cancer

Conditions: Prostate Cancer; Prostate Adenocarcinoma

Summary: recent guidelines now recommend multi parametric magnetic resonance imaging prior to biopsy for all men as an integral part of improved diagnosis of clinical significant prostate cancer. however, magnetic resonance imaging targeted biopsy is a strategy that focuses on maximizing detection of clinical significant prostate cancer, but this procedure has the disadvantage of leading to higher detection of clinically insignificant prostate cancers. one of the risk-stratifications developed to minimize the existing disadvantages and avoid unnecessary biopsy procedures is a strategy in which multi parametric magnetic resonance imaging and prostate-specific antigen density are used in combination. this is especially important in all patients with pi-rads (prostate imaging reporting and data system) 3 lesions which are also interpreted as indeterminate mpmri findings. current guidelines suggest that biopsy may be omitted in some patient groups with pi-rads 3 lesions in the risk-adapted strategy involving prostate-specific antigen density. the aim of this study was to evaluate the role of risk-adapted strategies involving prostate-specific antigen density in biopsy decision to avoid unnecessary biopsy vs the risk of missing clinical significant prostate cancer diagnosis in patients with pi-rads 3 lesions.


Eligibility criteria:
inclusion criteria: * patients who all had undergone multi parametric magnetic resonance imaging at our hospital * patients who all had undergone transrectal ultrasonography guided cognitive and fusion targeted biopsies exclusion criteria: * magnetic resonance imaging at exterior hospitals * insufficient image quality/artifacts * previous prostate biopsy and/or prior prostate cancer diagnosis

Keywords: prostate cancer risk-adapted strategy magnetic resonance imaging prostate-specific antigen density pirads
genetics of charcot marie tooth (cmt) - modifiers of cmt1a, new causes of cmt2

Conditions: Charcot-Marie-Tooth Disease, Type Ia (Disorder); HMSN

Summary: this project includes two projects. one is looking for new genes that cause charcot marie tooth disease (cmt). the other is looking for genes that do not cause cmt, but may modify the symptoms a person has.

this project is to understand modifier genes and how they influence the severity of disease expression, along with identifying new forms of cmt which have not been genetically determined. subjects who are eligible will either have cmt type 1a (cmt1a) or an unknown form of cmt. blood will be drawn and sent to the university of miami where they receive the coded sample and process it through exome sequencing. subjects will be told that this is optional.

Eligibility criteria:
inclusion criteria: all patients must agree to take part in the study and sign a consent form. a teenager (age 13-17 years) considering enrolling must agree to take part in the study and sign an assent form (depending on local ethics committee requirements). additional inclusion criteria are described below. inclusion criteria: cmt1a gene modifier study patients must have at least one of the following: 1. patient has a documented pmp22 duplication. and/or 2. patient has a first or second degree relative (parent, child, sibling, half- sibling, aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented pmp22 duplication and a clear link between that family member and the affected patient and a phenotype consistent with cmt1a. i. a clear link is necessary for a second-degree relative. for example, if a grandparent is affected and has a pmp22 duplication, and the parent does not have any signs, symptoms, or electrophysiology consistent with cmt1a, there is no clear link. ii. in cases where clear links are not available, genetic testing is required for the patient or the first degree family member who is not clearly affected. inclusion criteria - patients for cmt exome project a. patient has demonstrated neuropathy on nerve conduction studies or clinically diagnosed genetic neuropathy, in the opinion of the investigator or genetic counsellor. inclusion criteria - controls for cmt exome project 1. person is a family member of a cmt patient who is enrolled in the cmt exome project. and one of the following: 2. person does not have a peripheral neuropathy, in the opinion of the investigator or genetic counsellor. or 3. person is suspected to have a peripheral neuropathy, but has not been examined at an inc site. exclusion criteria 1. patient does not wish to participate or does not sign a consent form. 2. for cmt exome project, patient has a genetically confirmed form of cmt (i.e. mutation in mfn2 causing cmt2a, mutation in gars causing cmt2d, etc.). 3. patients with known neuropathy from a non-genetic source, such as chemotherapies (i.e. vincristine, taxol, cisplatin), diabetes, alcoholism will be evaluated independently so that genetic contributions to their effects on cmt1a phenotypes can also be analyzed.

Keywords: cmt cmt1a
food intake and blue dishware in residents living with dementia

Conditions: Food Preferences; Eating Behavior

Summary: blue dishware was alternated with white dishware for lunch and dinner for residents living with dementia. food consumption occurred in the home dining room and food was weighed before and after consumption to determine proportion consumed. eating challenges were also noted. within-participant comparisons were made to determine if food intake and eating challenges improved with the blue dishware condition.


Eligibility criteria:
inclusion criteria: * living in a residential care environment with dementia * informed consent of poa and assent of person living with dementia exclusion criteria: * did not come to the dining room to eat * required eating assistance * did not live on the study unit
ketor: effects of peri operative administration of ketamine on long term post thoracotomy pain

Conditions: Ketamine; Chronic Post Thoracotomy Pain; Thoracotomy; Pain; Neuralgia

Summary: we assessed the effects of the n methyl aspartate receptor antagonist ketamine on long-term post thoracotomy pain. we hypothesized that ketamine could prevent supersensitization of the central nervous system involved in this chronic neuropathic pain.

in this clinical, randomized prospective study, peri operative administration of ketamine was compared to placebo on long term post thoracotomy pain after a 2 months follow up period.

Eligibility criteria:
inclusion criteria: * patients eligible for thoracotomy or pneumectomy exclusion criteria: -

Keywords: ketamine chronic post thoracotomy pain nmda post operative
shock wave therapy versus low level laser therapy in patients with plantar fasciitis

Conditions: Plantar Fascitis

Summary: both shock wave therapy and low level laser therapy in plantar fasciitis are effective in improvement of such cases without any side effects but there are no previously published studies on the use of shock wave therapy versus low level laser therapy in plantar fasciitis and, hence, evidence of its acceptability and effectiveness compared with each other remains to be established.

plantar fasciitis is a result of degenerative irritation of the plantar fascia origin at the medial calcaneal tuberosity of the heel as well as the surrounding perifascial structures, it is a common problem accounting for approximately one million patient visits per year, it is often an overuse injury. as a result tight gastrocnemius, soleus, and/or other posterior leg muscles have also been commonly found in patients with this condition. shock wave therapy is thought to provide long lasting analgesia and stimulate the healing process, low level laser therapy has been used to relieve pain caused by plantar fasciitis, also stretching of the shortened and contracted plantar flexors may positively influence an individual's functional activities of daily living and decrease the risk of injury.

Eligibility criteria:
inclusion criteria: 1. age ranges from 40-60 years old. 2. both genders will be included. 3. unilateral plantar fasciitis. 4. duration of symptoms more than 4 weeks. 5. positive windlass test and negative tinel and calcaneus squeeze tests. 6. patients will be classified according to their bmi (18.5 - 24.9) kg/m2 exclusion criteria: 1. open wound, infection in plantar surface of foot. 2. history of foot surgery. 3. history of trauma or fracture in foot or ankle. 4. neuropathic pain as diabetes mellitus. 5. peripheral vascular disease. 6. calcaneal stress fracture or show evidence of a foreign body or tumor of the affected heel. 7. previously suffered a rupture or surgery of the plantar fascia. existing or prior osteomyelitis of the involved calcaneus.

Keywords: low level laser therapy shock wave therapy stretching exercises
fgfr inhibitor et0111 monotherapy in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a phase i, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of et0111 in patients with advanced solid tumors. it is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. et0111 will be administered orally once daily (qd) in 21-day treatment cycles.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. 2. aged at least 18 years at the time of icf signature. 3. histological or cytological confirmation of a solid tumor and have progressed despite standard therapy(ies), or are intolerant to standard therapy (ies), or have a tumor for which no standard therapy(ies) exists. locally recurrent disease must not be amenable to surgical resection or radiotherapy with curative intent (patients who are considered suitable for surgical or ablative techniques following down-staging with study treatment are not eligible). 4. estimated life expectancy of minimum of 12 weeks. 5. patient with solid tumors must have at least 1 lesion, not previously irradiated, that can be accurately measured at pre-dose as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computerised tomography (ct) or magnetic resonance imaging (mri) and which is suitable for accurate repeated measurements. 6. eastern cooperative oncology group (ecog) performance status 0 or 1 at icf signature. 7. males and females of child-bearing potential must agree to use effective contraception from the time icf signature until 12 weeks after the last dose. females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal. pregnancy tests for female of child-bearing potential must have a negative serum pregnancy test at screening. exclusion criteria: 1. have a history and/or current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, vascular system, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification.. 2. have current evidence of endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis etc. 3. as judged by the investigator, any evidence of significant ophthalmological abnormalities including but not limited to history or current evidence of retinal vein occlusion (rvo) or current risk factors for rvo, retinal macular degeneration, uncontrolled glaucoma, cataract or marked decrease in visual acuity, symptomatic severe dry eye, conjunctivitis, or corneal ulcer. prior bone marrow or organ transplantation 4. central nervous system metastatic disease, leptomeningeal disease, or metastatic cord compression. 5. prior therapy with any irreversible fgfr inhibitor.
cardiovascular outcome study to evaluate the effect of obicetrapib in patients with cardiovascular disease

Conditions: Atherosclerotic Cardiovascular Disease

Summary: this study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with atherosclerotic cardiovascular disease (ascvd) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.

this study will be a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of 10mg obicetrapib in participants with atherosclerotic cardiovascular disease (ascvd) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization. the prevail study

Eligibility criteria:
inclusion criteria: * males \& females ≥ 18 years age. * established ascvd including: * coronary artery disease * cerebrovascular disease * peripheral artery disease * on maximally tolerated lipid-modifying therapy * fasting ldl-c ≥ 55 mg/dl * fasting triglycerides \< 400 mg/dl * estimated glomerular filtration rate ≥ 30 ml/min exclusion criteria: * new york heart association class iii or iv heart failure or left ventricular ejection fraction \< 30% * have been hospitalized for heart failure within 5 years prior to screening * had non-fatal mi, non-fatal stroke, non-elective coronary revascularization and/or hospitalization for unstable angina or chest pain within past 3 months prior to screening * uncontrolled hypertension * diagnosis of homozygous familial hypercholesterolemia (hofh) * active liver disease * hba1c ≥10% * thyroid stimulating hormone (tsh) \> 1.5 times upper limit normal * creatine kinase \> 3 times upper limit normal * history of malignancy with surgery in past 3 years * history of alcohol or drug abuse within past 5 years * received treatment with investigational product or device within past 30 days excluding coronavirus treatment or vaccine * known allergy to study drug * participated in previous obicetrapib trial * taking gemfibrozil within 30 days screening
telcagepant (mk-0974) long-term safety study in adult participants with acute migraine (mk-0974-012)

Conditions: Migraine

Summary: the purpose of this study is to investigate the safety and tolerability of telcagepant (mk-0974) in the long-term treatment of acute migraine in adult participants. the primary hypothesis of this study is that telcagepant is well tolerated in the long-term treatment of acute migraine in adult participants.


Eligibility criteria:
inclusion criteria: * at least 1 year history of migraine (with or without aura) * females of child bearing potential must use acceptable contraception throughout trial * in general good health based on screening assessment exclusion criteria: * pregnant/breast-feeding (or is a female expecting to conceive during study period) * history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (hiv) disease * major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) * history of gastric, or small intestinal surgery, or has a disease that causes malabsorption * history of cancer within the last 5 years
preoperative hepatic arterial infusion chemotherapy

Conditions: Colorectal Liver Metastases

Summary: to assess the feasibility and results of liver resection after preoperative hepatic artery infusion (hai) chemotherapy with fudr.

between 1995 and 2004, 239 patients with isolated colorectal liver metastases received hai chemotherapy with neoadjuvant intent. fifty of these patients underwent subsequent curative liver resection (hai group). postoperative morbidity, liver function tests, and long term outcomes were evaluated. adverse events related to hai chemotherapy were also evaluated.

Eligibility criteria:
inclusion criteria: * unresectable liver metastases * potentially resectable liver metastases exclusion criteria: * extrahepatic disease